Targetnaya terapiya ploskokletochnogo raka golovy i shei


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Chemotherapy in the treatment of head and neck squamous cell carcinoma (HNSCC) is included in the current treatment regimens for locally advanced primary tumors as well as for disease recurrence or occurrence of distant metastases. However, clinicians do not deny the fact of increased toxicity of regimens used and their relatively low efficiency. The use of targeted therapies, in particular the drug cetuximab, has broadened our therapeutic options in the treatment of locally advanced tumors and provided a high efficacy of the 1st line chemotherapy for recurrent HNSCC and distant metastases from HNSCC.

Толық мәтін

Рұқсат жабық

Авторлар туралы

I. Romanov

Email: drromanov@mail.ru

Әдебиет тізімі

  1. GLOBOCAN 2012; http://globocan.iarc.fr/
  2. Cooper J.S, Pajak T.F., Forastiere A.A., Jacobs J., Campbell B.H., Saxman S.B., Kish J.A., Kim H.E., Cmelak A.J., Rotman M., Machtay M., Ensley J.F., Chao K.S., Schultz C.J., Lee N., Fu K.K.; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2004;350:1937-44.
  3. Le Q.T, Giaccia A.J. Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin. Cancer Res. 2003;9(12):4287-95.
  4. Penault-Llorca F. [Epidermal growth factor receptors: status evaluation methods and tumor expression]. Bull. Cancer. 2003;90:S186-91.
  5. Maurizi M., Almadori G., Ferrandina G., Distefano M., Romanini M.E., Cadoni G., Benedetti-Panici P., Paludetti G., Scambia G., Mancuso S. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br. J. Cancer. 1996;74:1253-57.
  6. Grandis J.R., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M., Drenning S.D., Tweardy D.J. Levels of TGF-β and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. 1998;90(11):824-28.
  7. Psyrri A., Seiwert T.Y., Jimeno A. Molecular pathways in head and neck cancer. Am. Soc. Clin. Oncol. Educ. Book. 2013;246-55.
  8. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer. 2001;37(Suppl. 4):S3-8.
  9. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 2001;7;2958-70.
  10. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Sh in D. M., Cohen R.B., Jones C. U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E.K., Ang K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006;354(6):567-78.
  11. Bonner J.A., Harari P.M., Giralt J., Cohen R.B., Jones C.U., Sur R.K., Raben D., Baselga J., Spencer S.A., Zhu J., Youssoufian H., Rowinsky E.K., Ang K.K. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-years survival data from a phase 3 randomised trial, and relation between cetuximab -induced rash and survival. Lancet Oncol. 2010;11(1):21-8.
  12. Ang K.K., Zhang Q.E., Rosenthal D.I., Nguyen-Tan P.F., Sherman E.J., Weber R.S., Galvin J.M., BonnerJ.A.,HarrisJ.,El-NaggarA.K.,GillisonM.L., Jordan R.C., Konski A.A., Thorstad W.L., Trotti A., Beitler J.J., Garden A.S., Spanos W.J., Yom S.S., Axelrod R.S. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J. Clin. Oncol. 2014;32(27):294-50.
  13. Lefebvre J., Pointreau Y., Rolland F., Alfonsi M., Baudoux A., Sire C., de Raucourt D., Malard O., Degardin M., Tuchais C., Blot E., Rives M., Reyt E., Tourani J.M., Geoffrois L., Peyrade F., Guichard F., Chevalier D., Babin E., Lang P., Janot F., Calais G., Garaud P., Bardet E. Induction chemotherapy followed by either chemoradio-therapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J. Clin. Oncol. 2013;31(7):853-59.
  14. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., Erfan J., Zabolotnyy D., Kienzer H.R., Cupissol D., Peyrade F., Benasso M., Vynnychenko I., De Raucourt D., Bokemeyer C., Schueler A., Amellal N., Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008;359(11):116-1127.
  15. Vermorken J.B., Trigo J., Hitt R., Koralewski P., Diaz-Rubio E., Rolland F., Knecht R., Amellal N., Schueler A., Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 2007;25(16):2171-77.
  16. Kies M.S., Garden A.S., Holsinger C., Papadimitrakopoulou V., ElNaggar A.K., Gillaspy K., LewinJ.,Lu C., VillalobosS.,Glisson B.S. Induction chemotherapy with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. 2006;24:285s. Abstract 5520.
  17. Mesia R., Henke M., Fortin A., Minn H., Yunes Ancona A.C., Cmelak A., Markowitz A.B., Hotte S.J., Singh S., Chan A.T., Merlano M.C., Skladowski K., Zhang A., Oliner K.S., VanderWalde A., Giralt J. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-labelphase 2 trial. Lancet Oncol. 2015;16(2):208-20.
  18. Giralt J, Trigo J., Nuyts S., et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16(2):221-32.
  19. Vermorken J.B., Stöhlmacher-Williams J., Davidenko I., Licitra L., Winquist E., Villanueva C., Foa P., Ro ttey S., Skla do wski K.,TaharaM.,Pai V.R., Faivre S., Blajman C.R., Forastiere A.A., Stein B.N., Oliner K.S., Pan Z., Bach B.A. SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14(8):697-710.
  20. Machiels J.P., Subramanian S., Ruzsa A., Repassy G.,LifirenkoI.,FlygareA.,SorensenP.,Nielsen T., Lisby S., Clement P.M. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011;12(4):333-43.
  21. Cohen E.E., Rosen F., Stadler W.M., Recant W., Stenson K., Huo D., Vokes E.E. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2003;21(10):1980-87.
  22. Argiris A., Ghebremichael M., Gilbert J., Lee J.W., Sachidanandam K., Kolesar J.M., Burtness B., Forastiere A.A. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J. Clin. Oncol. 2013; 31(11):1405-14.
  23. Stewart J.S., Cohen E.E., Licitra L., Van Herpen C. M., Khorprasert C., Soulieres D., Vodvarka P., Rischin D., Garin A.M., Hirsch F.R., Varella-GarciaM.,Ghiorghiu S., Hargreaves L., Armour A., Speake G., Swaisland A., Vokes E.E. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J. Clin. Oncol. 2009;27(11):1864-71.
  24. Harrington K., Berrier A., Robinson M., et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer. 2013;49(7):1609-18.
  25. Temam S., D'Cruz A., Jain M.M., D'Onofrio I., Manikhas G.M., Horvai G., Sun Y., Dietzsch S., Dubinsky P.,Holeckova P.,Mehanna H.,El-Hariry I., Franklin N., Biswas-Baldwin N., Legenne P., Wissel P.S., Netherway T., Santillana S., Bourhis J. Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. 2014;23(Suppl., abstr. 6005):5s.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>